How are energy investors positioned?
BROOMFIELD, Colo. - Aclarion, Inc. (NASDAQ: ACON, ACONW), a healthcare technology company with a market capitalization of $0.26 million, has announced its participation in the Selby Spine Conference, where Dr. Sigurd Berven will present on the company’s NOCISCAN platform. While the company maintains a strong liquidity position with a current ratio of 2.8, InvestingPro analysis indicates the company faces profitability challenges with a -69.45% gross margin. Dr. Berven’s presentation, scheduled for Friday, will discuss the platform’s use of MR Spectroscopy and augmented intelligence to noninvasively identify biomarkers for chronic low back pain, which are not visible on traditional MRI scans.
Aclarion’s NOCISCAN aims to set a new standard for diagnosing the source of discogenic pain, a significant global health issue affecting millions. The platform is designed to help physicians distinguish between painful and nonpainful discs in the lumbar spine by quantifying chemical biomarkers associated with disc pain. According to InvestingPro data, the company trades at an attractive Price/Book ratio of 0.1, suggesting potential value opportunity despite recent revenue challenges. Subscribers can access 14 additional ProTips and comprehensive financial analysis on the platform. This capability is expected to enable personalized treatment plans for patients with chronic low back pain.
The presentation by Dr. Berven at the Selby Spine Conference in Deer Valley, UT, will highlight the evidence-supported capabilities of NOCISCAN. The platform combines MR Spectroscopy data with proprietary signal processing techniques and augmented intelligence algorithms to provide insights into the location of a patient’s low back pain. This information, when used alongside other diagnostic tools, is intended to help physicians optimize treatment strategies.
Chronic low back pain is a prevalent condition, with an estimated 266 million people worldwide suffering from degenerative spine disease and low back pain. Aclarion’s approach with NOCISCAN represents a novel solution in the field of spine surgery and chronic pain management. While the company’s revenue declined 41.41% in the last twelve months, InvestingPro’s Fair Value analysis suggests the stock may be undervalued at current levels.
NOCISCAN is the first SaaS platform of its kind to offer a noninvasive method for physicians to assess lumbar spine discs, leveraging cloud technology to process and analyze MRI data for this purpose. The company’s focus on optimizing clinical treatments through advanced technology aligns with a growing trend in healthcare towards personalized medicine.
This news is based on a press release statement from Aclarion, Inc. The company has cautioned that the press release contains forward-looking statements subject to uncertainties and risks that could affect their plans and future results of operations and financial condition.
In other recent news, Aclarion, Inc., a medical laboratory services provider, has executed a reverse stock split at a ratio of 1-for-335, a move aimed at maintaining compliance with Nasdaq’s continued listing standards. The reverse stock split, which has reduced the number of issued and outstanding shares from approximately 169.4 million to about 500,000 post-split shares, was approved by the company’s board and stockholders.
This development has also affected Aclarion’s outstanding warrants, stock options, and restricted stock units, with adjustments made to the number of shares into which these securities are convertible or exercisable. The reverse stock split has resulted in the company’s gross proceeds reaching approximately $14.55 million, and it is expected to increase its stockholders’ equity to around $10.5 million.
In addition to this, Aclarion has terminated its At-The-Market Issuance Sales Agreement with Ascendiant Capital Markets, LLC, ending its ability to sell shares of its common stock through the "at the market" offering. During the term of the Sales Agreement, Aclarion sold approximately 1.6 million shares, resulting in gross proceeds of around $300,000.
Furthermore, Aclarion has extended its equity line agreement with White Lion Capital, LLC, introducing new pricing options for shares sold under the agreement and issuing White Lion 560,915 commitment shares. These recent developments are part of Aclarion’s broader business strategy.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.